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The tumor-associated antigens, up-to-date methods for their identification and immunotherapeutics 
strategies for cancer treatment have been reviewed. The main attention has been focused on the antigens 
identified by SEREX (Serological identification of antigens by recombinant expression cloning) metho­
dology and the categories of tumor-associated antigens (i. e. identified by SEREX approach) have been 
listed. The main immunotherapeutic approaches have been classified, the successes of active specific 
immunotherapy based on immunodominant peptides of tumor-associated antigens have been described. 
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Tumor-associated antigens and methods for their 
identification. The identification and molecular char­
acterization of tumor antigens in the tumor-bearing 
host are the major tasks in the tumor immunology. An 
analysis of humoral and cellular immune responses 
against such antigens in cancer patients indicates for 
a long time that tumor-associated antigens (TAA) do 
exist and are recognized by patient's immune system. 
These antigens are the potential targets for the 
antigen specific cancer immunotherapy and cancer 
diagnostics. 
The first useful antigens — alfa fetoprotein, a 
serum marker for hepatoma and germ cell tumors, 
and carcinoembryonic antigen (CEA), a serum mar­
ker for colon and other epithelial cancers were 
identified by the analysis of heteroimmune sera 
obtained from rabbits and other animals immunized 
with human cancer cells [1, 2] . In the 1970s and 
1980s, the monoclonal antibody technology was exp­
loited for the identification of molecules on tumor 
cells that could be used as diagnostic markers or as 
target structures for the immunotherapeutic approa-
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ches with monoclonal antibodies. Some of these 
efforts yielded new therapeutic tools, such as the anti-
CD20 antibody «rituximab» which showed consider­
able activity and has been licensed for the treatment 
of B-cell lymphomas [3 ]. However, the approaches of 
active immunotherapy require the identification of 
target structures, immunogenic in the autologous 
tumor-bearing host. There are two different opinions 
regarding the methods for searching antigens for 
active immunotherapy. 
First, numerous studies on experimental animals 
showed that the cellular, rather than the humoral, 
immune response was in charge of the rejection of 
transplanted tumors or allogenic (genetically dif­
ferent) tissues. With the exception of antibodies 
against the growth factor receptors on cancer cells, 
the administration of antibodies has little effect on the 
growth of solid tumors. Thus, a significant effort 
should be directed at identification of the antigens 
recognized by human T-lymphocytes [4, 5] . On the 
other hand, it is now commonly accepted that immune 
recognition of tumors is a concerted action. Hence, 
high-titer circulating tumor-associated antibodies of 
the immunoglobulin G (IgG) class may reflect a 
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significant host-tumor interaction and identify such 
gene products, against which at least cognate T-
helper cells and specific cytotoxic T-cells should exist 
[6]. The present review describes the categories of 
TAA and methods for their identification are as well 
as some immunological strategies for cancer immu­
notherapy, based on molecular identification of TAA. 
The main attention is focused on the serological 
approach to search for TAA (SEREX), but T-cell-
defined tumor antigens and techniques for their 
identification are also considered. 
Since T-cells play an essential role in tumor 
growth inhibition and cancer cells eradication, first of 
all some useful techniques have been developed to 
identify the cancer antigens capable of eliciting cel­
lular immune response. The genetic approach repre­
sents the transfection of genomic DNA or cDNA 
libraries into the cells expressing the appropriate 
major histocompatibility complex (MHO molecules, 
followed by the identification of the transfectants 
using cytokine release or lysis by human T-cells 
(CTL — cytotoxic T-lymphocytes) with specific anti­
tumor reactivity [7 ]. The biochemical technique offers 
the elution of peptides from tumor cells or from MHC 
removed from tumor cells surface and detection of 
fractions capable of stimulating antitumor T-cells 
after pulsing purified peptides onto antigen-presenting 
cells. The triple quadrapole mass spectrometric tech­
niques have been used to sequence the minute quan­
tities of peptides obtained [8 ]. 
Another method is an identification of tumor 
antigens by in vitro sensitization of T-cells against 
possible tumor antigens [9]. T-cells culture suc­
cessfully sensitized in vitro against these antigens 
have been tested for their ability to recognize the 
intact tumor cells, and that provides strong evidence 
that these candidate proteins represent the tumor 
antigens [9]. 
The mechanism of eradication of cancer cells by 
T-lymphocytes involves both CD8 cytotoxic T-cells 
and CD4 T-helper cells that recognize antigens pre­
sented as small peptides by the MHC classes I and 
II. CD8 T-cells recognize peptides derived from 
intracellular cytoplasmic proteins, digested in pro-
teasomes and presented via the endoplasmatic re­
ticulum on the cell surface by class I MHC. In 
contrast, CD4 cells use a different intracellular path­
way for engulfed extracellular proteins, digested to 
peptides in intracellular endosomes and presented on 
cell surface by class II MHC molecules. Since CD8 
CTL can lyse tumor cells directly and destroy large 
tumor masses in vivo, several tumor antigens, pre­
sented by MHC I, have been defined using the 
tumorreactive CD8 T-cells. Clinical trials using the 
tumor antigens have evidenced some therapeutic ef­
fects inhibiting tumor growth. However, the overall 
immune response was too weak and transient to 
eradicate cancer cells in the majority of patients who 
were immunized. Though a growing body of evidences 
suggests that CD4 T-cells play a central role in 
initiating and maintaining immune responses against 
cancer [10], the optimal vaccination might require the 
participation of both CD4 and CD8 T-cells to ge­
nerate a strong and long-lasting antitumor immunity. 
Although MHC II restricted tumor antigens are clear­
ly important, some problems exist for their iden­
tification due to special requirements for MHC II 
antigen processing and presentation. 
The ability of antigen-presenting cells (APC) to 
endocytose proteins and to present peptides by MHC 
II has been utilized to identify antigens recognized by 
CD4 T-cells, although so far few antigens have been 
identified using this approach [11]. A genetic tar­
geting expression (GTE) approach has been de­
veloped that allows the screening of cDNA library 
fused to genes encoding invariant chain (Ii) sequences 
for identification of MHC II restricted antigens, 
designed to guide the transfected proteins into the 
class II presentation pathway [12]. 
Thus, during the last few years, effective stra­
tegies of identification of TAA recognized by specific 
T-cells have resulted in the characterization of various 
antigens, such as the melanoma differentiation an­
tigens, CEA, epithelial cell adhesion molecule, HER-
2\new, Wilms tumor protein, proteinase 3, NY-ESO-
1, antigens of MAGE, BAGE, GAGE, SSX-families, 
etc. as described by Renkvist et al. [13]. The authors 
have summarized more than 60 MHC class I related 
TAA, recently identified [13]. A completed list of 
T-cell epitopes can be found in the peptide database 
of T-cell defined tumor antigens (http://www.can-
cerimmunity.org/peptidedatabase/Tcellepitopes.htm). 
SEREX approach and categories of tumor-as­
sociated antigens. Unfortunately, all the techniques 
listened above are technically challenging because 
they require the establishment of autologous CTL 
lines and tumor cell lines from the same patient, a 
task not achievable for most epithelial tumor types 
[14]. An alternative technique that circumvents these 
limitation has been developed by Pfeundschuh and 
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his colleagues [15]. They call their approach SEREX 
for «serological identification of antigens by recom­
binant expression cloning*. SEREX has been de­
signed to isolate tumor antigens that elicit high-titer 
IgG response in human hosts. In their initial ap­
plication of this method, Pfeundschuh and his col­
leagues identified MAGE-A1 and tyrosinase, two 
antigens originally cloned as CTL targets, indicating 
that SEREX can detect tumor antigens that elicit the 
CTL-mediated immune response [15]. 
SEREX allows a systematic and unbiased search 
for antibody responses and direct molecular definition 
of immunogenic tumour proteins, based on their 
reactivity with autologous patient serum. In the SE­
REX approach, a cDNA expression library is const­
ructed from a fresh tumour specimen, and cloned into 
A phage expression vectors. The resulting recombinant 
phages are then used to infect Escherichia coli. 
Recombinant proteins expressed during the lytic in­
fection of the bacteria are transferred onto nitro­
cellulose membranes, which are incubated with di­
luted (1:100—1:1000) and depleted from anti E. coli 
and anti A phage antibodies serum from the auto­
logous patient. Clones reactive with high-titre anti­
bodies are identified using an enzyme-conjugated 
secondary antibody specific for human IgG. Positive 
clones are subcloned to monoclonality, and the nuc­
leotide sequence of the cDNA insert is determined. 
cDNA sequence analysis via database searching is 
performed to define whether the cDNA inserts are 
derived from novel genes or cancer-associated known 
genes. The domains and/or motifs for putative func­
tion and cellular localisation of the antigens can be 
also identified. The SEREX approach characterized 
by several features is reviewed by Sahin et al. [16]. 
The main of them is using fresh tumor specimens that 
circumvent in vitro the artifacts associated with the 
short- and long-term tumor cell culture. This elimi­
nates the need of establishing tumor and CTL cell 
lines. 
However, the data accumulated over recent years 
evidence that antigen repertoire detectable by the 
conventional SEREX approach to be limited [6 ]. This 
might be in part attributed to the fact that the 
potential antigens modificated posttranslationally re­
main undetected in bacterial expression systems. The 
posttranslational modifications play an important role 
in the proper function of many proteins and also 
affect their immunogenicity. To overcome some of the 
inherent problems with the conventional SEREX sys­
tem, recombinant antigen expression on yeast sur­
face* (RAYS) has been proposed recently to establish 
a eukaryotic expression system in yeast. Yeasts have 
the advantage that recombinant proteins can be 
expressed on the cell surface in a more naturally 
folded, partially glycosylated manner [17]. A number 
of other modifications of the original method have 
been proposed recently. Subtractive approaches allow 
enrichment of the cDNA library for tumor specific 
transcripts [18 ]. cDNA Libraries may also be prepared 
from sources of specific interest, such as amplified 
chromosomal regions obtained by microdissection 
[19]. Another alternative cloning strategy for TAA 
with a possibility of high throughput analysis of 
patient sera and tumor libraries has been projected 
newly. The pJuFo phage surface display, allowing 
display of recombinant tumor proteins on the surface 
of M13 filamentous phage, has been explored for 
cloning TAA in prostate cancer [20 ]. 
In 1995 the SEREX program was initiated under 
supervision of Dr L. Old, the head of Ludwig Institute 
for Cancer Research (LICR). The SEREX colla­
borative group involve the investigators from the 
University of Saarland (Hamburg, Germany), Ludwig 
Institute Branches in New York, San Diego (USA), 
Melbourne (Australia), and London (UK, University 
College); Aichi Cancer Center (Naoya, Japan), Kran-
kenhaus Nordwest (Frankfurt, Germany), Mie Uni­
versity School of Medicine (Mie, Japan), Moscow 
State University (Moscow, Russia), and the Institute 
of Molecular Biology and Genetics (Kyiv, Ukraine). 
During the last few years, SEREX has been 
applied to a wide range of tumor types, including 
melanoma, renal cancer, astrocytoma, Hodgkin's di­
sease [15], oesophageal cancer [21], gastric cancer 
[22], colon cancer [23], lung cancer [24], breast 
cancer [25], prostate cancer [26], leukaemia [27] 
and thyroid cancer [28]. For the systematic docu­
mentation and archiving of sequence data and im­
munological characteristics of identified antigens, the 
electronic SEREX database, established by the LICR, 
is accessible to the public http://www.licr.org/SE-
REX.html. To date more than 2,000 antigens have 
been listed in the SEREX database [6 ]. According to 
their expression patterns in normal and malignant 
tissues, several categories of tumor antigens can be 
distinguished. The table 1 lists the categories of the 
tumor antigens identified. 
Cancer-testis (CT) antigens are a fascinating 
category of tumor antigens with the expression res-
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Table 1 
Categories of human cancer antigens 
tricted to male germ cells in the testis, in some cases 
in ovary and in throphoblast, but not in adult somatic 
tissues. In malignancy, the gene regulation is dis­
rupted, resulting in CT antigen expression in tumors 
of various type. Many of the genes coding for these 
antigens are mapped to chromosome X and exist as 
multimember families. The representatives of this 
category, MAGE [29], BAGE [30], and GAGE [31], 
were initially identified as targets for the cytotoxic 
T-cells. The HOM-Mel-40 antigen (gene SSX-2), 
detected in the melanoma library, is the first CT 
antigen identified by SEREX [32]. The SEREX 
analysis of esophageal cancer resulted in the iden­
tification of the NY-ESO-1 gene with restricted exp­
ression in testis and various cancers [21 ]. The 
success of SSX and NY-ESO-1 cloning prompted a 
series of the SEREX studies of various tumor types, 
and that led to the identification of additional CT 
antigens, i. e. CT7/MAGE-C1, SCP-1, HOM-TES-
85, Ctage-1, OY-TES-1, and most recently CAGE as 
reviewed by Scanlan et al. [14]. To date appro­
ximately 20 CT antigens families have been identified 
and the list of CT antigens has been greatly expan­
ded through serological expression cloning (SEREX). 
Recently, several new techniques have been used for 
CT antigen discovery based on restricted pattern of 
the CT gene expression. Representational difference 
analysis (RDA) led to the identification of LAGE1, 
CT10, SAGE, the differential display — CTpl l . The 
oligonucleotide array analysis allowed to discover 
MMA-1A gene, and through bioinfonnatic approach 
some CT antigens were identified — BRDT (CT9), 
fertilin p (CT15), CT16 and CT17 [14]. With the 
exception of SCP-1, OY-TES-1, and CT15 (fertilin 
/?), the biological function of the most CT antigens is 
not known. CT antigens are characterized by hetero­
geneous protein expression in cancer, likely cor­
relation with tumor progression, immunogenicity in 
cancer patients, and induction of expression by hypo-
methylation and histone acetylation. A demethylation 
state in cancer (whatever its cause) may induce the 
gametogenic program and result in the activation of 
silent CT genes. Alternatively, the demethylation may 
be an intrinsic part of the gametogenic program, and 
therefore a consequence, not a cause, of switching on 
the gametogenic program and CT genes in cancer 
[33]. Cancer-testis antigens are ideal targets for 
cancer immunotherapy. 
Differentiationantigens are expressed in tumor in 
a lineage-associated manner, but found also in normal 
cells of the same origin. Melan A/MART-1 [34, 35], 
tyrosinase [36], gplOO [37, 38], gp75/TRP-l [39] 
antigens have been found in malignant melanomas, a 
particularly rich source of differentiated antigens, the 
expression of which is limited to melanomas as well 
as melanocytes, the cells of this tumor origin. The 
next examples are glial fibrillary acidic protein 
(GFAP), which is antigenic in malignant glioma, but 
also expressed in brain cells [40], and recently found 
NY-BR-1 expressed in 70—80 % of breast cancer, 
25 % of prostate cancer as well as in normal breast, 
prostate and testis tissues [41 ]. 
Amplified / overexpressed antigens coded by amp­
lified or overexpressed genes have also been identified 
through SEREX. Among them are HOM-RCC-3.1.3, 
new carbonic anhydrase identified in renal cancer 
[42], Bax inhibitor protein 1—in glioma [40], 
eLF-4y — in squamous cell lung cancer [19], galectin 
9 — in Hodgkin's disease [43 ], indicating that an­
tigen overexpression can lead to immunogenicity, as 
in the case of HER2/new [44 ]. 
Mutated antigens have rarely been demonstrated 
using the serological approach, mutated p53 being the 
only example [23 ]. As reviewed by Rosenberg [4 ], a 
variety of mutated antigens, MUM-1, CDK4, caspase-
8, /?-catenin, and their mutated epitopes have been 
identified with autologous T-cells. 
Splice variants antigens have been detected by 
serological approach, for example, the Hodgkin's 
disease-associated variant of restin [15] and gastric 
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cancer associated splice variant of TACC1 antigen 
[45]. 
Virus encoded antigens are expressed in different 
malignancies in humans. Many of viruses associated 
with oncogenesis can present proteins on the induced 
cancer antigens that can serve as the targets for 
immune attack. These viral antigens can be also used 
as targets for preventive or therapeutic vaccination. 
However, the induction of neutralizing antibodies 
against envelope viral proteins can prevent the an­
tigen-specific immune response in cancer patients 
immunized with the recombinant viruses vaccines 
[46]. 
Cancer-related autoantigens art expressed ubiq­
uitously and at similar levels in both healthy and 
malignant tissues. Cancer-related autoantigens, in 
contrast to non-cancer-related antigens, that elicit 
antibody response only in cancer patients, and not in 
healthy individuals that elicit antibody response with 
similar frequencies in both healthy individuals and 
cancer patients. This might result from tumor-as­
sociated post-translational modifications or changes in 
antigen processing and/or presentation in tumor cells. 
An example is HOM-MEL-2.4 that represents the 
CCAAT enhancer binding protein [7 ]. 
Thus, systematic application of antibody-based 
(SEREX) and CTL-based methods has led to the 
definition of growing number of TAA. The multitude 
of tumor-specific antigens identified by the SEREX 
approach demonstrates that there is ample immune 
recognition of human tumors by the autologous host's 
immune system. Together with the identification of 
T-lymphocyte epitopes, a picture of immunological 
profile of cancer is emerging. Knowledge of cancer 
immunome (i. e. the sum of all the proteins expressed 
by tumor-bearing autologous host) provides a new 
basis for understanding tumor biology and for deve­
lopment of new diagnostic and therapeutic strategies 
for cancer. Besides their roie as targets for cancer 
vaccination, the identified antigens may be useful as 
new molecular markers of malignant diseases. The 
value of each of these markers or a combination of 
them for diagnostic or prognostic evaluation of cancer 
patients has to be determined by correlation between 
markers expression and clinical data. Furthermore, 
the immune system is a sensitive biodetector, which 
may determine structural and regulative alterations 
and may therefore point to gene products of sig­
nificance for neoplastic transformation or tumour 
progression [47]. 
Development of immunotherapeutic strategies. 
The first clear indication that immunological mani­
pulation could cause the regression of established 
invasive human cancers came from the studies on 
administration of interleukin-2 (IL-2) to patients with 
metastasis kidney cancer or melanoma [48]. The 
discovery of tumor antigens and the identification of 
their immunodominant epitopes have shifted emphasis 
to the utilization of these antigens to mediate the 
destruction of growing cancers in humans. Attempts 
are in progress to develop immunotherapies based on 
the specific stimulation of immune reactions against 
defined tumor antigens rather than on the non­
specific stimulation of the immune system that is 
characteristic of the prior approaches. 
Specific as well as non-specific immunotherapies 
fall into either adoptive or active immunotherapy 
(tabl. 2). Early studies on non-specific adoptive 
immunotherapy of tumor-bearing patients involved 
the transfer of limphokine-activated killer (LAK) cells 
that recognize and lyse cancer cells in vitro [49 ]. For 
these purposes TIL (tumor infiltrated lymphocytes 
from respective tumors) could be expanded to 10 1 0— 
10" cells and then adoptively transferred along with 
IL-2 into melanoma patients [50 ]. Non-specific active 
immunotherapy used either autologous or allogenic 
whole cancer cells or cancer cells extracts for immu­
nization of cancer patients. As reviewed by Rosenberg 
[46 ], the vaccines based on cancer cells were derived 
from: whole cancer cells (both autologous and allo­
genic preparation), gene-modified cancer cells (genes 
encoding cytokines or co-stimulatory molecules) or 
cancer cell extracts (lysates, membranes and heat-
shock proteins) and cancer cells fused to APC. 
Measurable specific immune responses were rarely 
detected following this approach, and the efficacy of 
immunization was reflected only by clinical deve­
lopment [51 ]. 
The identification of human cancer antigens has 
opened a new era of specific cancer immunotherapy. 
To date specific cancer immunotherapy (tabl. 2) 
based either on the adoptive transfer of the in vitro 
generated lymphocytes with high level of specific 
reactivity against tumor antigens (passive or adoptive 
immunotherapy) or on immunization against specific 
cancer antigens (active immunotherapy), represents 
attractive approaches. Cancer antigens has facilitated 
the in vitro generation of anti-tumor T-cells which can 
be expanded and used for specific adoptive immu­
notherapy [52]. The genetic modification of these 
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Table 2 
Immunotherapeutic strategies 
IAK-limphokine-activated Whole cancer cells, gene modified T-cells, generated in vitro against Purified cancer antigens (natural 
killer cells, TIL-tumor cancer cells (genes encoding specific cancer antigens, immu- or recombinant), synthetic 
infiltrated lymphosytes cytokines or co-stimulatory nodominant peptides or utilizing peptides alone or pulsed onto 
molecules), cancer cell extracts tumor antigens pulsed onto APC APC, «naked DNA», recombinant 
(lysates, membranes and heat- and the same T-cells genetically viruses (adenovirus, vaccinia or 
shock proteins), cancer cells fused modified (by inserting genes en- avipox), recombinant bacteria 
with APC coding anti-tumor or chemokine (Bacille Calmete-Guerin and 
receptors and anti-tumor cytoki- Listeria) 
nes), specific monoclonal antibody 
lymphocytes to improve their anti-tumor efficacy (for 
instance, by inserting genes, encoding anti-tumor or 
chemokine receptors, or genes, encoding anti-tumor 
cytokines) is under active investigation [53 ]. In vitro 
sensitization techniques, using repeated in vitro sti­
mulation against immunodominant peptides or uti­
lizing tumor antigens pulsed onto professional APC, 
have resulted in the in vitro generation of T-cells with 
extremely high antitumor activity. Clinical protocols 
utilizing the specific adoptive transfer of these in vitro 
sensitized cells, are in progress as well [24 ]. Specific 
active immunotherapy suggests using purified cancer 
antigens (natural or recombinant), synthetic peptides 
alone or pulsed onto APC, «naked» DNA (for exam­
ple, plasmids), recombinant viruses (adenovirus, vac­
cinia or avipox) and recombinant bacteria (Bacille 
Calmete-Guerin and Listeria) as cancer vaccine, and 
represents the most perspective and promising ap­
proach. The advantage of antigen-specific vaccination 
is a possibility of monitoring specific vaccine-induced 
immune responses that is for the identification of 
mechanisms mediating tumor regression in vivo [46 ]. 
The efficacy of cancer vaccines is affected by the 
immunogenicity of antigens, the route of immu­
nizations and tumor features making them susceptible 
to immunologic recognition [51 ]. The main goal of 
cancer vaccination is the induction of an effective 
specific response against tumor cells which spares the 
cells of normal tissues. With respect to specificity, 
several classes of antigens may be suitable targets; in 
addition to the CT antigens, these include diffe­
rentiation antigens, tumor associated overexpressed 
gene products, mutated gene product and tumor-
specific splice variants [6]. 
A number of vaccines based on tumor associated 
antigens, i. e. SEREX-defined antigens, have been 
developed for the needs of specific active immu­
notherapy. Several steps of the analysis are required 
before SEREX-defined antigens become potential tar­
gets for the active immunotherapy trials in cancer 
patients as reviewed by Jager et al. [54 ]. 
As the first step, a careful expression analysis of 
each antigen has to be performed by comparing the 
cDNA sequence with EST databases. The antigens 
with restricted expression according to the database 
analysis are being tested by RT-PCR using a panel 
of normal and tumor tissues cDNAs to confirm the 
restricted mRNA expression pattern. 
The antigens that show a tumor/tissue-restricted 
expression pattern, undergo a serological analysis to 
define the frequency of humoral immune responses in 
sera derived from cancer patients and normal indi­
viduals. A limited number of sera can be tested using 
the phage-plaque assay; for large-scale serology, the 
recombinant protein has to be produced and tested in 
Western blot assays or ELISA. 
The antigens with tumor/tissue-specific expres­
sion and detectable humoral immune responses in 
tumor patients have to be analyzed for T-cell recog­
nition. An approach called the reverse immunology 
approach allows testing the entire protein sequence of 
the respective antigen for potential MHC I binding 
sequences (see CancerlmmunomeDB, SYFPEITHI 
database of MHC ligands and peptide motifs at 
http: / /www.bmi-heidelberg.com/syfpeithi/). Peptide-
specific CTL can be generated upon in vitro sti­
mulation, and recognition of target cells expressing 
the antigenic protein will be documented. The tumor 
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antigens that represent the target antigens for CD8 
T-cells can be used to immunize the patients with 
antigen-positive tumors. 
The following list summarizes the steps of ana­
lyzing SEREX-defined antigens as potential targets 
for CD8 T-cells: SEREX analysis — Database ana­
lysis — Expression analysis — Serology-MHC-motif 
search for epitopes — ELISPOT assays (T-cell reac­
tivity) — Immunotherapy trial [54 ]. 
Among a number of cancer vaccine trials per­
formed with tumor antigens, «naked» DNA, APC, 
tumor cells, cytokines, co-stimulatory molecules and 
so on, the immunization strategy with immuno­
dominant peptides derived from tumor antigens is the 
most attractive. Promising immunologic and clinical 
results were observed after vaccination with the 
peptides derived from the CT antigens MAGE-3 [55 ] 
and NY-ESO-1 [56]. The detectable peptide-specific 
CD8 T-cell responses were associated with the reg­
ression of metastatic lesions in single patients [55]. 
The objective tumor regression was observed in single 
patients under continued immunization with the pep­
tide derived from melanocyte differentiation antigens 
MelanA/MART-1 [57] and tyrosinase [58]. The 
overexpressed antigens, such as HER-2\new, wild-
type 53 and viral antigens, for example, the proteins 
of Human pappiloma viruses may also represent 
useful targets for therapeutic and/or preventive im­
munologic intervention [51 ]. The immunization stra­
tegies with MHC II restricted peptides are incre­
asingly studied in vaccine trials [59, 60]. The anti­
genic peptides derived from different cancer antigens 
(used either alone or combined with cytokines i. e., 
IL-2, IL-12, GM-CSF or adjuvants i. e., incomplete 
Freund's adjuvant, QS21) lead to the induction of 
strong specific CD T-cell responses [51 ]. The immu-
nogenicity of peptide epitopes may be signficanty 
increased in vitro by modifying specific amino acid 
anchoring residues (e. g., exchange of cysteine with 
valine or alanine) [61 ]. Enhanced immunologic ef­
fects were observed in clinical studies using dendrite 
cells loaded with the peptide derived from cancer 
antigens, i. e. MAGE-3, MelanA\MART-l, that were 
related with disease stabilization and regression of 
metastasis melanoma lesions in single patients [62]. 
The local immune reactions, i. e., DTH reactions, 
inflammatory enlargement of lymph nodes, were ob­
served after the antigen administration depending on 
the route of immunization: intradermal, intralym-
phatic or subcutaneous. The overall goal of clinical 
vaccine trials is the induction of CD8 and/or CD4 
T-cell responses against the defined cancer antigens. 
Currently, the ELISPOT assay and structure-based 
peptide-MHC-tetramer assay measuring the mag­
nitude of CD8 T-cell responses in the peripheral 
blood, in tumor-infiltrating lymphocytes, and in drai­
ning lymph nodes were established to be the most 
sensitive methods to determine the function and the 
quantity of the vaccine induced effector cells. In the 
function-based ELISPOT assay, antigen-specific cells 
are detected on the basis of proximal cytokine pro­
duction [63]. The structure based peptide-MHC-
tetramer assay is the method of identifying antigen-
specific T-cells on the basis of T-cell receptor recog­
nition by its ligand, the peptide-MHC complex [64]. 
Novel immunological tools that can be used not only 
to quantify the antigen-specific response, but also to 
analyze the phenotype and function of individual 
effector cells are described in the review of Yee and 
Greenberg [65]. 
In response to effective immunotherapy, the tu­
mor cells may evolve the mechanisms that allow them 
to escape immune recognition. Such immunoselection 
can cause an outgrowth of the tumor cell population 
that has lost the expression of a given target antigen 
[66]. A significant form of the immune escape is an 
ability of tumor cells to evolve the mechanisms that 
impede the antigen processing and presentation, in­
cluding the alteration or loss of the expression of 
MHC alleles, a2-microglobulin and transporter mo­
lecules associated with the antigen processing (TAP). 
Tumor cells can also secrete the immunosupressive 
cytokines such as transforming growth factor (TGF)-
(3 and IL-10, which can inhibit the T-lymphocyte 
effector function [67]. Usage of polyvalent vaccines, 
specific for several tumor-associated antigens, or 
vaccination with antigens required by the tumor for 
maintenance of it 's malignant phenotype (e. g. telo-
merase), can circumvent this form of the immune 
escape [67, 68]. The information on the composite 
expression of different antigens in a given tumor is 
crucial for the design of polyvalent vaccine strategies. 
It is important to assess the number of patients that 
are suitable for a combined or sequential vaccination 
with two or more tumor antigens, because such a 
strategy could have the potential of reducing or even 
preventing the in vivo selection of antigen loss tumor 
cell variants [67]. 
Hence, during last two decades the successes of 
immunotherapy resulted in the development of diverse 
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modern immunotherapeutic strategies for cancer tre­
atment. The identification of tumor-associated anti­
gens has opened a new era of tumor immunology and 
unlimited possibilities for development of active spe­
cific immunotherapy. Novel immunotherapeutic ap­
proaches to cancer treatment and vaccines of new 
generation have been developed due to the successes 
in the field of molecular biology, cell immunology and 
genetic engineering. Modern methods of monitoring 
immune response make possible to investigate the 
molecular mechanisms of immune response during 
immunotherapeutic manipulations that allow to under­
stand the origin of cancer and to improve the treat­
ment of cancer diseases. 
P. Г. Кіямова, В. В. Філоненко 
Асоційовані з пухлиною антигени та розвиток 
імунотерапевтичних стратегій 
Резюме 
Зроблено огляд асоційованих з пухлиною антигенів, методів 
їхньої ідентифікації та існуючих на сьогодні імунотерапев­
тичних стратегій щодо лікування раку. Особливу увагу приді­
лено антигенам, ідентифікованим з використанням методо­
логії SEREX (серологчіна ідентифікація антигенів за допомо­
гою рекомбінантно експресованих клонів) та наведено кате­
горії асоційованих з пухлиною антигенів (у тому числі, 
ідентифікованих із застосуванням SEREX). Класифіковано 
головні імунотерапевтичні підходи та описано успіхи актив­
ної специфічної імунотерапії за допомогою імунодомінантних 
пептидів асоційованих з пухлиною антигенів. 
Ключові слова: імунотерапія, антиген, рак. 
Р. Г. Киямова, В. В. Филоненко 
Ассоциированные с опухолью антигены и развитие 
иммунотерапевтических стратегий 
Резюме 
Сделан обзор ассоциированных с опухолью антигенов, методов 
их идентификации и существующих на сегодняшний день 
иммунотерапевтических стратегий для лечения рака. Основ­
ное внимание уделено антигенам, идентифицированным с по­
мощью методологии SEREX (серологическая идентификация 
антигенов с использованием рекомбинантно екпрессируемых 
клонов) и перечислены категории ассоциированных с опухолью 
антигенов (в том числе идентифицированных SEREX). Клас­
сифицированы основные иммунотерапевтические подходы и 
описаны успехи активной специфической иммунотерапии с 
помощью иммунодоминантных пептидов ассоциированных с 
опухолью антигенов. 
Ключевые слова: иммунотерапия, антиген, рак. 
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